Despite receiving the endorsement of the Big Ten Conference (“Big Ten”) and the Southeastern Conference (“SEC”) in early August of this year, the Protect College Sports Act of 2026 (S. 4668), a bill introduced with bipartisan support that would establish a national framework for college athletics, did not get a floor vote in the U.S. Senate before its annual August recess. Meanwhile, the complicated ecosystem surrounding college sports continues to evolve at a dizzying pace, with consequential battles to define the new normal for universities, student-athletes, and other constituencies being fought in statehouses and courtrooms rather than on the playing fields. Attorneys Brian Cromer and Daniel Boswell take a look at the Act in this Stites & Harbison Client Alert.

When a construction project goes sideways, a mechanic’s lien can be one of the most powerful tools available to secure payment. Tennessee law provides contractors, subcontractors, suppliers, and other project participants with lien rights, but those rights must be carefully preserved. Tennessee’s statutes establish detailed requirements governing perfection, enforcement, and release of mechanic’s liens. Unfortunately, many lien claims fail not because the claim is invalid, but because procedural requirements were not followed. Construction attorney Ann Murphy takes a look at those requirements in this Stites & Harbison Client Alert.

When we last checked in on our friend the Terminator (Artificial Intelligence: Accounting for AI in Construction Documents), we left off at the front end — accounting for AI at the time of contract. But the machines did not stop at the contract. As James Cameron’s 1991 sequel taught us, the real story is what happens after the paperwork, when the technology walks off the page and onto the site. This is that sequel.

In recent years, courts have struggled with when a generic drug company can be held liable for induced infringement, that is, encouraging doctors to prescribe a drug in a way that is still protected by a patent. This issue arises from the way the U.S. drug approval system balances innovation and access. When a brand name pharmaceutical company develops a new drug, it files a New Drug Application (NDA) with the Federal Drug Administration (FDA) and often secures multiple patents. These typically include not only patents on the drug itself, but also patents covering specific methods of using the drug to treat particular conditions. Over time, additional method of treatment patents may issue as new clinical uses are discovered. IP attorney Kimberly Vines takes a look at the issue in this Stites & Harbison Client Alert.